HitGen-Backed Equity Investment Fund to Invest RMB40 Million for Controlling Stake in Moshang Intelligence, an AI Pharma Data Service Provider Release Time：2025-12-29

On December 20, 2025, HitGen Inc. ("HitGen", SSE: 688222.SH) announced that Chengdu Rongchuang HitGen Equity Investment Fund Partnership (LP) ("Rongchuang HitGen Fund") would invest RMB40 million to increase its capital in Moshang Intelligence Technology (Chengdu) Co., Ltd. ("Moshang Intelligence"). Upon completion, the Rongchuang HitGen Fund will become the controlling stakeholder of Moshang Intelligence, owning a 51% share.

Moshang Intelligence provides comprehensive services with a focus on life sciences data infrastructure, AI model development, and pharmaceutical consulting. While unlocking synergies between the two companies in R&D and knowledge system construction, "data + technology" platform development, and commercialization exploration, this investment is expected to strengthen HitGen's competitiveness in life sciences knowledge engineering by improving the company's capabilities in the fields of life sciences data and AI technology.